Hopp til hovedinnhold

Osteoporose

Sist oppdatert: Sist revidert:
Sist revidert av:


Definisjon:
Systemisk skjelettsykdom med redusert beinmasse og endringer av beinvevets mikroarkitektur, som fører til økt skjørhet av beinvev og økt bruddrisiko. Økt risiko postmenopausalt, og økende risiko med økende alder for begge kjønn
Forekomst:
Hyppig tilstand, livstidsrisiko for osteoporotisk brudd blant kvinner er 40%
Symptomer:
Lårhals- eller armbrudd hos eldre, brudd i ryggen med eller uten smerter
Funn:
Ev. redusert kroppshøyde ved ryggvirvelbrudd
Diagnostikk:
Røntgen-bilder bekrefter brudd. Osteoporose bekreftes ved DXA-måling
Behandling:
Fysisk aktivitet og røykeslutt er viktig. Medikamenter ved etablert osteoporose eller høy risiko for fraktur
  1. Qaseem A, Forciea MA, McLean RM, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017. pmid:28492856 PubMed  
  2. Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med 2016; 374:254-262. www.nejm.org  
  3. World Health Organization (WHO). WHO scientific group on the assessment of osteoporosis at primary health care level: summary meeting report. Siden besøkt 30.09.2019. www.who.int  
  4. Berntsen GKR. Interpretation of forearm bone mineral density: the Tromsø study. Dr.gradsavhandling, Univ. i Tromsø. ISM skriftserie, nr 56, 2000.
  5. Norsk Endokrinologisk Forening. Osteoporose. I Nasjonal veileder i endokrinologi. Sist oppdatert 30.09.2021. Siden lest 21.07.2022. metodebok.no  
  6. Syversen U, Halse JI. Medikamentell behandling av osteoporose. Tidsskr Nor Lægeforen 2003; 123: 2263-4. PubMed  
  7. Lowe KE, Mansfield KE, Delmestri A, et al. Atopic eczema and fracture risk in adults: A population-based cohort study. J Allergy Clin Immunol 2019. doi:10.1016/j.jaci.2019.09.015 DOI  
  8. Starup-Linde J, Rosendahl SB, Storgaard M, Langdahl B. Management of osteoporosis in patients living with HIV - a systematic review and meta-analysis. J Acquir. Immune Defic Syndr 2020; 83: 1-8. pmid:31809356 PubMed  
  9. Vestergaard P, Laursen LC, Schwarz P, Brixen K. Glukokortikoidinduceret osteoporose. Ugeskr Læger 2005; 167: 898-900. PubMed  
  10. Crndall CJ, Larson JCLaCroix AZ, et al. Risk of Subsequent Fractures in Postmenopausal Women After Nontraumatic vs Traumatic Fractures. JAMA Intern Med 2021. pmid:34096979 PubMed  
  11. Joakimsen RM, Fønnebø V. Bør det innføres screening for osteoporose i Norge? Tidsskr Nor Lægeforen 2001; 121: 615-8. Tidsskrift for Den norske legeforening  
  12. Borgen TT, Eriksen EF. Benmarkører ved behandling av osteoporose. Tidsskr Nor Legeforen 2021; 141: 1600-2. doi:10.4045/tidsskr.21.0119 DOI  
  13. Norsk kvalitetsforbedring av laboratorieundersøkelser (Noklus). Anbefalte analyser ved ulike kliniske problemstillinger. Lipoproteinforstyrrelser. Siden besøkt 28.09.2020 www.noklus.no  
  14. Nasjonal faglig retningslinje for bildediagnostikk ved ikke-traumatiske muskel- og skjelettlidelser. Anbefalinger for primærhelsetjenesten. Oslo, Helsedirektoratet 2014 www.helsebiblioteket.no  
  15. Cummings SR, Lui L-Y, Eastell R, Allen IE. Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates A Meta-analysis. JAMA Intern Med 2019. pmid:31424486 PubMed  
  16. Hinton PS, Nigh P, Thyfault J. Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: a 12-month randomized, clinical trial. Bone 2015;79:203-212. PMID: 19421702 PubMed  
  17. Zhang S, Huang X, Zhao X, et al. Effect of exercise on bone mineral density among patients with osteoporosis and osteopenia: A systematic review and network meta-analysis. J Clin Nurs 2021. pmid:34725872 PubMed  
  18. Sherrington C, Whitney JC, Lord SR, et al. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc. 2008 Dec;56(12):2234-43. PMID: 19093923. PubMed  
  19. Santesso N, Carrasco-Labra A, Brignardello-Petersen R. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2014; 3: CD001255. doi:10.1002/14651858.CD001255.pub5 DOI  
  20. Koike T, Orito Y, Toyoda H, et al. External hip protectors are effective for the elderly with higher-than-average risk factors for hip fractures. Osteoporosis Int 2009; 20: 1613.20. pmid:19137351 PubMed  
  21. Yao P, Bennett D, Mafham M, et al. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. JAMA Netw Open 2019; 2: e1917789. pmid:31860103 PubMed  
  22. Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014 Apr 14;4:CD000227. Cochrane (DOI)  
  23. Reid I, Bolland M, et.al. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2013. doi:10.1016/S0140-6736(13)61647-5. DOI  
  24. Bolland MJ, Leung W, Tai V, et al. Calcium intake and risk of fracture: systematic review. BMJ. 2015 Sep 29;351:h4580. doi: 10.1136/bmj.h4580 DOI  
  25. Warensjö E, Byberg L, Melhus H, et al. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 2011; 342: d1473. BMJ (DOI)  
  26. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA 2017; 318: 927-938. pmid:28898378 PubMed  
  27. Rosen HN, Rosen CJ, Schmader KE. Overview of the management of osteoporosis in postmenopausal women. UpToDate 2022. Sist oppdatert juni 2022. Siden lest 21.07.2022 www.uptodate.com  
  28. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394: 1159-68. pmid:31474332 PubMed  
  29. RELIS Vest. Østrogen i behandling av osteoporose hos postmenopausale kvinner. RELIS database 2021. relis.no  
  30. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377: 1417-27. pmid:28892457 PubMed  
  31. Legeforeningen. Gjør kloke valg. Anbefalinger. Siden besøkt 11.02.2021 www.legeforeningen.no  
  32. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, Coyle D, Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD001155. DOI: 10.1002/14651858.CD001155.pub2. DOI  
  33. Deardorf WJ, Cenzer I, Nguyen B, et al. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis A Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2021. pmid:34807231 PubMed  
  34. Eriksen EF, Halse J. Når seponere bisfosfonater?. Tidsskr Nor Legeforen 2012; 132: 1630-2. Tidsskrift for Den norske legeforening  
  35. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783-9. Journal of the American Medical Association  
  36. Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofacial Surg Clin N Am 2007; 19: 487-98. PubMed  
  37. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft . N Engl J Med 2011; 364: 1728-37. DOI: 10.1056/NEJMoa1010650 DOI  
  38. Serrano AJ, Begona L, Anitua E, Cobos R, Orive G. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol. 2013 Dec;29(12):1005-14. PMID: 24063695 PubMed  
  39. Reid DM, Devogelaer J-P, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-63. PMID: 19362675 PubMed  
  40. Faggruppe for osteoporose og benhelse, Norsk ortopedisk forening. Behandlingsveileder for menn og kvinner ≥ 50 år, med lavenergibrudd. Publisert 2015. legeforeningen.no  
  41. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006 Jun;17(6):897-907. PMID: 16547070 PubMed  
  42. Brown JP, Roux C, Ho PR, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.. Osteoporos Int. 2014 Mar 28. pmid:24676847 PubMed  
  43. Diédhiou D, Cuny T, Sarr A, et al. Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review. Ann Endocrinol (Paris). 2015 Dec;76(6):650-7. Epub 2015 Nov 27. pmid: 26639186 PubMed  
  44. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019; 104: 1595-622. pmid:30907953 PubMed  
  45. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013. doi:doi:10.1016/S0140-6736(13)60856-9 DOI  
  46. Kendler DL, Marin F, Zerbini CAF, et al.: Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018; 391: 230-40. pmid:29129436 PubMed  
  47. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60: 3346-55. pmid:19877063 PubMed  
  48. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007 Aug;18(8):1023-31. PMID: 17308956 PubMed  
  49. Newman M, Minns Lowe C, Barker K. Spinal Orthoses for Vertebral Osteoporosis and Osteoporotic Vertebral Fracture: A Systematic Review. Arch Phys Med Rehabil 2015. pmid:26615791 PubMed  
  50. Hagen G, Wisløff T, Falch J, et al. Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway. Rapport fra kunnskapssenteret nr 10 - 2011.
  51. Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016 Oct 5;10:CD001347. pmid: 27706804 PubMed  
  52. Zhao J-G, Zeng X-T, Wang J, et al. Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults A Systematic Review and Meta-analysis. JAMA 2017; 318: 2466-82. pmid:29279934 PubMed  
  53. Burt LA, Billington EO, Rose MS, et al. Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial. JAMA. 2019 Aug 27;322(8):736-745. PMID: 31454046 PubMed  
  54. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365: 1621-8. PubMed  
  55. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of supplementation with calcium and cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330: 1003-6. British Medical Journal  
  56. Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012; 366: 225-33. New England Journal of Medicine  
  57. Chen P, Krege JH, Adachi JD, et al. Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res 2009; 24: 495-502. pmid:19016585 PubMed  
  58. Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011; 22: 983-91. pmid:21052642 PubMed  
  • Erik Fink Eriksen, professor, MD, DMSc, Dept. of endocrinology, Oslo University Hospital, Oslo
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL

Tidligere fagmedarbeidere

  • Jan Falch, overlege, Medisinsk avdeling, Aker sykehus, Oslo